Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B1accaabf69fca1fc6cdff2f75fdc322e> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B1accaabf69fca1fc6cdff2f75fdc322e NCIT_P378 "NCI" @default.
- B1accaabf69fca1fc6cdff2f75fdc322e type Axiom @default.
- B1accaabf69fca1fc6cdff2f75fdc322e annotatedProperty IAO_0000115 @default.
- B1accaabf69fca1fc6cdff2f75fdc322e annotatedSource NCIT_C62510 @default.
- B1accaabf69fca1fc6cdff2f75fdc322e annotatedTarget "A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells." @default.